Eton Pharmaceuticals Inc
ETON16.830USD
-0.160-0.94%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
451.34MMarket Cap
LossP/E TTM
More Details of Eton Pharmaceuticals Inc Company
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
Eton Pharmaceuticals Inc Info
Ticker SymbolETON
Company nameEton Pharmaceuticals Inc
IPO dateNov 09, 2018
CEOBrynjelsen (Sean E)
Number of employees31
Security typeOrdinary Share
Fiscal year-endNov 09
Address21925 W Field Pkwy Ste 235
CityDEER PARK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code60010-7278
Phone18477877361
Websitehttps://etonpharma.com/
Ticker SymbolETON
IPO dateNov 09, 2018
CEOBrynjelsen (Sean E)
Company Executives of Eton Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Sean E. Brynjelsen
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
864.94K
-19.54%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
93.42K
--
Mr. Paul V. Maier
Mr. Paul V. Maier
Independent Director
Independent Director
84.75K
--
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
84.75K
-54.72%
Mr. James R. Gruber
Mr. James R. Gruber
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
21.71K
-34.20%
Ms. Ipek Erdogan-Trinkaus
Ms. Ipek Erdogan-Trinkaus
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. David C. Krempa
Mr. David C. Krempa
Chief Business Officer
Chief Business Officer
--
--
Ms. Jennifer (Jenn) Adams
Ms. Jennifer (Jenn) Adams
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sean E. Brynjelsen
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
864.94K
-19.54%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
93.42K
--
Mr. Paul V. Maier
Mr. Paul V. Maier
Independent Director
Independent Director
84.75K
--
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
84.75K
-54.72%
Mr. James R. Gruber
Mr. James R. Gruber
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
21.71K
-34.20%
Ms. Ipek Erdogan-Trinkaus
Ms. Ipek Erdogan-Trinkaus
Chief Commercial Officer
Chief Commercial Officer
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
18.93M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Opaleye Management Inc.
10.66%
EcoR1 Capital, LLC
7.57%
BlackRock Institutional Trust Company, N.A.
5.82%
The Vanguard Group, Inc.
5.01%
Nantahala Capital Management, LLC
4.38%
Other
66.55%
Shareholders
Shareholders
Proportion
Opaleye Management Inc.
10.66%
EcoR1 Capital, LLC
7.57%
BlackRock Institutional Trust Company, N.A.
5.82%
The Vanguard Group, Inc.
5.01%
Nantahala Capital Management, LLC
4.38%
Other
66.55%
Shareholder Types
Shareholders
Proportion
Hedge Fund
21.89%
Investment Advisor
21.61%
Investment Advisor/Hedge Fund
16.73%
Research Firm
5.68%
Individual Investor
4.30%
Bank and Trust
0.10%
Venture Capital
0.09%
Pension Fund
0.06%
Insurance Company
0.04%
Other
29.50%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
197
16.82M
61.06%
-98.00
2025Q3
198
16.82M
61.07%
+73.58K
2025Q2
187
16.74M
59.55%
+2.45M
2025Q1
147
14.23M
51.82%
+331.79K
2024Q4
120
13.23M
40.20%
+3.64M
2024Q3
91
9.60M
36.18%
+1.31M
2024Q2
87
8.28M
33.62%
+960.54K
2024Q1
87
7.24M
33.51%
-1.37M
2023Q4
89
7.16M
31.90%
+250.49K
2023Q3
92
6.91M
28.21%
+911.27K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Opaleye Management Inc.
2.86M
10.66%
+7.93K
+0.28%
Jun 30, 2025
EcoR1 Capital, LLC
2.03M
7.57%
+91.26K
+4.71%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.40M
5.22%
+1.08M
+334.29%
Jun 30, 2025
The Vanguard Group, Inc.
1.31M
4.89%
+211.21K
+19.18%
Jun 30, 2025
Nantahala Capital Management, LLC
1.18M
4.38%
--
--
Jun 30, 2025
Brynjelsen (Sean E)
864.94K
3.23%
-210.00K
-19.54%
Jun 05, 2025
Geode Capital Management, L.L.C.
592.87K
2.21%
+294.62K
+98.78%
Jun 30, 2025
Westside Investment Management, LLC
472.79K
1.76%
-20.86K
-4.23%
Jun 30, 2025
Morgan Stanley & Co. LLC
311.99K
1.16%
+186.23K
+148.08%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
First Trust Active Factor Small Cap ETF
0.11%
iShares Micro-Cap ETF
0.09%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.07%
Vanguard US Momentum Factor ETF
0.06%
iShares Russell 2000 Growth ETF
0.03%
ProShares Hedge Replication ETF
0.02%
Global X Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
View more
First Trust Active Factor Small Cap ETF
Proportion0.11%
iShares Micro-Cap ETF
Proportion0.09%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.07%
Vanguard US Momentum Factor ETF
Proportion0.06%
iShares Russell 2000 Growth ETF
Proportion0.03%
ProShares Hedge Replication ETF
Proportion0.02%
Global X Russell 2000 ETF
Proportion0.02%
Proshares Ultra Russell 2000
Proportion0.02%
iShares Russell 2000 ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Eton Pharmaceuticals Inc?
The top five shareholders of Eton Pharmaceuticals Inc are:
Opaleye Management Inc. holds 2.86M shares, accounting for 10.66% of the total shares.
EcoR1 Capital, LLC holds 2.03M shares, accounting for 7.57% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.40M shares, accounting for 5.22% of the total shares.
The Vanguard Group, Inc. holds 1.31M shares, accounting for 4.89% of the total shares.
Nantahala Capital Management, LLC holds 1.18M shares, accounting for 4.38% of the total shares.
Opaleye Management Inc. holds 2.86M shares, accounting for 10.66% of the total shares.
EcoR1 Capital, LLC holds 2.03M shares, accounting for 7.57% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.40M shares, accounting for 5.22% of the total shares.
The Vanguard Group, Inc. holds 1.31M shares, accounting for 4.89% of the total shares.
Nantahala Capital Management, LLC holds 1.18M shares, accounting for 4.38% of the total shares.
What are the top three shareholder types of Eton Pharmaceuticals Inc?
The top three shareholder types of Eton Pharmaceuticals Inc are:
Opaleye Management Inc.
EcoR1 Capital, LLC
BlackRock Institutional Trust Company, N.A.
Opaleye Management Inc.
EcoR1 Capital, LLC
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Eton Pharmaceuticals Inc (ETON)?
As of 2025Q4, 197 institutions hold shares of Eton Pharmaceuticals Inc, with a combined market value of approximately 16.82M, accounting for 61.06% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.01%.
What is the biggest source of revenue for Eton Pharmaceuticals Inc?
In FY2025Q2, the -- business generated the highest revenue for Eton Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
